Nuclear magnetic resonance imaging agent Gadobutrol 138071-82-6_Viwit

Product

/

Products and Services

/

Active pharmaceutical ingredients

/

Active pharmaceutical ingredients

/

Nuclear magnetic resonance imaging agent Gadobutrol 138071-82-6

News Center

Viwit Pharmaceutical Co., Ltd. participated in CPHI Worldwide 2022 held in Frankfurt Germany from November 1st to November 3rd. 2022-11-09 12:43:00

As the world's largest pharmaceutical industry exhibition, CPHI has been successfully held for 30 years. It displays the entire pharmaceutical supply chain, from API, P-MEC to FDF. It becomes the largest annual gathering of pharmaceutical professionals all over the world. Viwit met old friends and new business partners at CPHI. We displayed a wonderful enterprise image with our products and services, and promoted our international business through CPHI.

Viwit participants in CPhI China 2019, booth: W2B28 2019-06-18 01:34:00

CPhI China 2019 will be held at Shanghai New International Expo Center on June 18-20, 2019. Welcome to patronage of Viwit, booth number: W2B28. If you would like to make an appointment in advance, please email us at service@viwit.com.

CPhI India 2018, Booth No. 4.H15 2018-12-12 01:34:00

CPhI India 2018, Booth No. 4.H15 CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.

Welcome participants in CPhI India 2018, booth number: 4.H15 2018-12-12 01:32:00

Welcome participants in CPhI India 2018, booth number: 4.H15 CPhI India 2018 will be held from December 12th to 14th, 2018 at the Expo Center in Delhi, India. Welcome to patronage of Viwit, booth number: 4.H15. If you want to make an appointment in advance, please send an email to service@viwit.com

Congratulations to Viwit Pharmaceutical Co., Ltd. for passing GMP certification of Health Canada 2018-10-11 01:32:00

In September 2018, Viwit's API factory in Tengzhou, Shandong Province ushered in a five-day GMP audit by Health Canada. In the end, Welcome successfully completed the GMP inspection by Health Canada and achieved excellent results. Any regulatory inspection is a challenge, but it is also a great opportunity to demonstrate your capabilities. Viwit has always adhered to the concept of cGMP standards and is committed to following high standards of quality management system. The successful on-site inspection by Health Canada is another milestone achievement by Viwit as a world-leading pharmaceutical and health company. Viwit will continue to follow the cGMP standards for each operation procedure to provide the market with safer and higher quality products.

Welcome participants in CPhI Worldwide 2018, booth number: 7A80 2018-10-09 01:33:00

CPhI Worldwide 2018 will be held on October 9-11, 2018 at the Madrid International Convention and Exhibition Center in Spain. Welcome to patronage of Viwit, booth number: 7A80. If you want to make an appointment in advance, please send an email to service@viwit.com

Nuclear magnetic resonance imaging agent Gadobutrol 138071-82-6

【Alias】 Gadobutrol
【Catalog Number 】AP5100
【CAS #】 138071-82-6
【Molecular Formula】C18H31GdN4O9
【Molecular Weight】604.71

English Name : Gadobutrol

CAS# : 138071-82-6





产品描述

[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

Alias	Gadobutrol
Catalog Number	AP5100
CAS #	138071-82-6
Molecular Formula	C₁₈H₃₁GdN₄O₉
Molecular Weight	604.71
Structural Formula
Product Introduction CAS 138071-82-6	Gadobutrol, English name is Gadobutrol, American Chemical Abstracts Registration Number is cas 138071-82-6. Gadobutrol (CAS 138071-82-6) is a gadolinium-containing contrast agent introduced by Bayer Pharmaceuticals. This medication is used for magnetic resonance imaging (MRI) examinations of the patient's central nervous system. In addition, succinyl alcohol was approved by the US Food and Drug Administration (FDA) in March 2011.

扫二维码用手机看

Previous：

Overactive bladder medication Mirabegron 223673-61-8

Next：

Nuclear magnetic resonance imaging agent Gadobenate Dimeglumine 127000-20-8



search

Confirm

Close

About Us

R&D and Innovation

Products

Innovation

Sustainable

News Center

Join Us

Contact Us

VIWIT 沪ICP备12014533号-2

EN

中文